Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 1/20 | 0.69 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.69 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.69 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.69 |
| ▸ | DOT1L | Q8TEK3 | 6/20 | 0.68 |
| ▸ | DNMT3B | Q9UBC3 | 2/20 | 0.68 |
| ▸ | PRMT7 | Q9NVM4 | 2/20 | 0.68 |
| ▸ | AMD1 | P17707 | 2/20 | 0.61 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.61 |
| ▸ | PNMT | P11086 | 1/20 | 0.60 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.60 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.56 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.56 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.56 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.51 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.49 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9940467 | 1.00 | PI4KA (0.69) | PI4KAPI4K2BPI4K2API4KBDOT1L | |
| SCHEMBL9970197 | 0.88 | PI4KA (0.65) | PI4KAPI4K2BPI4K2API4KBDOT1L | |
| SCHEMBL9940489 | 0.88 | PI4KA (0.65) | PI4KAPI4K2BPI4K2API4KBDOT1L | |
| SCHEMBL9940497 | 0.88 | PI4KA (0.65) | PI4KAPI4K2BPI4K2API4KBDOT1L | |
| SCHEMBL4868400 | 0.87 | PI4KA (0.76) | PI4KAPI4K2BPI4K2API4KBDOT1L | |
| SCHEMBL14344749 | 0.86 | PI4KA (0.77) | PI4KAPI4K2BPI4K2API4KBDOT1L | |
| SCHEMBL9941044 | 0.85 | PI4KA (0.62) | PI4KAPI4K2BPI4K2API4KBDOT1L | |
| SCHEMBL9941051 | 0.85 | PI4KA (0.62) | PI4KAPI4K2BPI4K2API4KBDOT1L | |
| SCHEMBL16128949 | 0.85 | PI4KA (0.82) | PI4KAPI4K2BPI4K2API4KBDOT1L | |
| SCHEMBL460252 | 0.85 | PI4KA (0.82) | PI4KAPI4K2BPI4K2API4KBDOT1L |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160068559-A1 | Modulators of Histone Methyltransferase, and Methods of Use Thereof | Epizyme, Inc. | 2016-03-10 | — | — | US | disclosed |
| US-20160068559-A1 | Modulators of Histone Methyltransferase, and Methods of Use Thereof | Epizyme, Inc. | 2016-03-10 | — | — | US | disclosed |
| US-20160068559-A1 | Modulators of Histone Methyltransferase, and Methods of Use Thereof | Epizyme, Inc. | 2016-03-10 | — | — | US | disclosed |
| US-9029343-B2 | Modulators of histone methyltransferase, and methods of use thereof | Epizyme, Inc. (US) | 2015-05-12 | — | — | US | disclosed |
| US-9029343-B2 | Modulators of histone methyltransferase, and methods of use thereof | Epizyme, Inc. (US) | 2015-05-12 | — | — | US | disclosed |
| US-9029343-B2 | Modulators of histone methyltransferase, and methods of use thereof | Epizyme, Inc. (US) | 2015-05-12 | — | — | US | disclosed |
| US-20130310333-A1 | Modulators of Histone Methyltransferase, and Methods of Use Thereof | Epizyme, Inc. (US) | 2013-11-21 | — | — | US | disclosed |
| US-20130310333-A1 | Modulators of Histone Methyltransferase, and Methods of Use Thereof | Epizyme, Inc. (US) | 2013-11-21 | — | — | US | disclosed |
| EP-2646455-A2 | MODULATORS OF HISTONE METHYLTRANSFERASE, AND METHODS OF USE THEREOF | Epizyme, Inc. (US) | 2013-10-09 | — | — | EP | disclosed |
| WO-2012082436-A2 | MODULATORS OF HISTONE METHYLTRANSFERASE, AND METHODS OF USE THEREOF | Epizyme, Inc. (US) | 2012-06-21 | — | — | WO | disclosed |
| WO-2012082436-A2 | MODULATORS OF HISTONE METHYLTRANSFERASE, AND METHODS OF USE THEREOF | Epizyme, Inc. (US) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160068559-A1 | Modulators of Histone Methyltransferase, and Methods of Use Thereof | EHMT1, EHMT2, HNMT | PI4KA 1844/4885PI4K2B 1901/4885PI4K2A 1942/4885 |
| US-20130310333-A1 | Modulators of Histone Methyltransferase, and Methods of Use Thereof | EHMT1, EHMT2, HNMT | PI4KA 1844/4885PI4K2B 1901/4885PI4K2A 1942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.